Overview

Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure

Status:
Completed

Trial end date:
2019-01-30

Target enrollment:
0

Participant gender:
All

Summary

Now many cases reported failure to HCV treatment with Sofosbuvir/ Daclatasvir. retreat those patients is challenging. So, we aimed to Study the efficacy and safety of Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin versus Sofosbuvir /ombitasvir/ paritaprevir/ritonavir/ribavirin in the management of hepatitis C patients who failed to prior Sofosbuvir/ Daclatasvir regimens in an open-labeled randomized trial.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Assiut University

Collaborators:

Sohag University
South Valley University

Treatments:

Ribavirin
Ritonavir
Simeprevir
Sofosbuvir

Criteria

Inclusion Criteria:

- Patients with proven CHC genotype 4

- 18 years old or more,

- prior HCV treatment failure to sofosbuvir /daclatasvir

- compensated liver disease.

Exclusion Criteria:

- Patients with combined HCV/HBV co-infection, hepatocellular carcinoma (HCC),
decompensated liver cirrhosis (Child-Pugh score above 6), and non-genotype 4 were
excluded.